JNJ Stock Recent News

Johnson & Johnson's Q4 2024 earnings missed EPS expectations but broadly met revenue targets; full-year 2024 showed 4.3% sales growth and $5.79 EPS. Despite short-term challenges, including Stelara's patent loss, JNJ's long-term growth strategy focuses on high-growth markets and promising pipeline products. JNJ's MedTech division showed strong performance, with significant investments in cardiovascular and surgical robotics expected to drive future growth.

The FDA approves Johnson & Johnson's sNDA for Spravato as a monotherapy for adults with treatment-resistant depression.

Johnson & Johnson (NYSE:JNJ ) Q4 2024 Earnings Conference Call January 22, 2025 8:00 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joaquin Duato - Chairman and Chief Executive Officer Joseph Wolk - Executive Vice President, Chief Financial Officer Jennifer Taubert - Executive Vice President, Worldwide Chairman, Innovative Medicine John Reed - Executive Vice President, Innovative Medicine, R&D Tim Schmid - Executive Vice President, Worldwide Chairman, MedTech Conference Call Participants Terence Flynn - Morgan Stanley Joshua Jennings - TD Cowen Alexandria Hammond - Wolfe Research Tim Anderson - Bank of America Lawrence Biegelsen - Wells Fargo Chris Schott - JPMorgan David Roman - Goldman Sachs Operator Good morning and welcome to Johnson & Johnson's Fourth Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session of the conference.

JNJ beats estimates for fourth-quarter earnings and sales. Its sales guidance for 2025 falls short of expectations.

Ahead of today's regular stock market trading session, pre-market futures are picking up where they left off Tuesday afternoon: higher. Continued optimism for a pro-growth Trump administration are sending major indexes to loftier reaches: the Dow is currently +145 points (+0.33%), the S&P 500 is +34 (+0.56%) and the Nasdaq +219 points (+1.01%).

Johnson & Johnson shares faced pressure on Wednesday as soft sales guidance for the coming year cast a shadow over expectation-beating fourth-quarter profit. Adjusted net earnings of US$4.95 billion were down 11.1% year on year in the fourth quarter, J&J reported, but ahead of consensus expectations for US$4.88 billion.

The headline numbers for Johnson & Johnson (JNJ) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible violations of federal securities laws. J&J issued a press release on January 8, 2025, announcing that "on January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation.

Blue-chip earnings reports continue to roll in , with results from Procter & Gamble Co (NYSE:PG) and Johnson & Johnson (NYSE:JNJ) on tap.

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or "the Company") (NYSE:JNJ). Investors who purchased J&J securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/JNJ.